About Addiction Therapeutix

Addiction Therapeutix is developing proprietary in-licensed medications for the treatment of various addictions and related illnesses. The company is located in the Technology Innovation Center in the Milwaukee County Research Park in Wauwatosa, Wisconsin, U.S.A.

The company is focused on the development of compounds for Co-Morbid Alcoholism and Anxiety and Opioid and Nicotine Addiction. Alcohol dependence (i.e., alcoholism) is a medical condition which is estimated to affect over 18 million people in the United States alone. In addition, the World Health Organization estimates that 3 – 8% of all global deaths are related to alcohol consumption (1). Opioids are frequently prescribed by physicians because of their analgesic and pain-relieving properties. Medications that are within this group are referred to as prescription narcotics and include morphine, codeine, oxycodone, and related drugs. According to the 2008 U.S. Survey on Drug Use and Health, 4.7 million Americans use prescription pain killers non-medically. In the same study, it is estimated that there are 70.9 million are current users of tobacco products (2).

Despite the high prevalence of these addictions, there are a disproportionately small number of individuals receiving pharmacotherapy for these substance abuse disorders. As a result, we believe there is a significant unmet clinical need for medications that may be effective and more readily accepted than what is currently available. The company is also in discussions with other institutions regarding the potential in-licensing of additional compounds complementary to its existing portfolio.

We are in various early stages of animal studies with these compounds and have shown promising results. Additional information about our compounds and current state of development is contained in the Science and Technology portion of our website.

1. Rehm J., Mathers, C. et al Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet 2009; 373: 2223 – 2233.

2. 2008 U.S. National Survey on Drug Use and Health–Substance Abuse and Mental Health Services Administration (SAMSHA)–NIH